Historical yearly usage of vancomycin.
作者信息
Kirst H A, Thompson D G, Nicas T I
出版信息
Antimicrob Agents Chemother. 1998 May;42(5):1303-4. doi: 10.1128/AAC.42.5.1303.
Abstract
摘要
相似文献
1
Historical yearly usage of vancomycin.万古霉素的历年使用情况。
Antimicrob Agents Chemother. 1998 May;42(5):1303-4. doi: 10.1128/AAC.42.5.1303.
2
Spread of vancomycin-resistant enterococci: differences between the United States and Europe.耐万古霉素肠球菌的传播：美国与欧洲的差异。
Infect Control Hosp Epidemiol. 1998 Aug;19(8):546-51. doi: 10.1086/647871.
3
Comment: Vancomycin-resistant enterococci.
Ann Pharmacother. 1996 Dec;30(12):1500. doi: 10.1177/106002809603001229.
4
Vancomycin-resistant enterococci and empirical vancomycin for CAPD peritonitis.
Perit Dial Int. 1997 Nov-Dec;17(6):617-8.
5
Vancomycin resistant enterococci--a threat to the nephrologist on the horizon? Glycopeptide-resistant enterococci and ICDC-recommendations for a limited use of glycopeptides.
Nephrol Dial Transplant. 1996 Dec;11(12):2402-6. doi: 10.1093/oxfordjournals.ndt.a027202.
6
Vancomycin-resistant enterococci. Mechanism and clinical relevance.耐万古霉素肠球菌。作用机制及临床意义。
Infect Dis Clin North Am. 1997 Dec;11(4):851-65. doi: 10.1016/s0891-5520(05)70393-7.
7
Summaires for patients. Factors associated with the development of antibiotic-resistant bacteria.患者摘要。与抗生素耐药菌产生相关的因素。
Ann Intern Med. 2001 Aug 7;135(3):S-27. doi: 10.7326/0003-4819-135-3-200108070-00005.
8
Vancomycin-resistant enterococci.
Pharmacotherapy. 1995 Sep-Oct;15(5):684-5. doi: 10.1002/j.1875-9114.1995.tb02882.x.
9
Avoparcin ban.
Vet Rec. 1997 Jan 25;140(4):103-4.
10
引用本文的文献
1
Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin's clinical durability.耐万古霉素金黄色葡萄球菌（VRSA）可以克服抗生素耐药的代价，并且可能威胁到万古霉素的临床持久性。
PLoS Pathog. 2024 Aug 29;20(8):e1012422. doi: 10.1371/journal.ppat.1012422. eCollection 2024 Aug.
2
Tetrachloromaxamycins: Divergent Total Synthesis and Initial Assessments.四氯麦角霉素：不同的全合成及初步评估。
J Org Chem. 2024 Sep 6;89(17):12701-12710. doi: 10.1021/acs.joc.4c01927. Epub 2024 Aug 21.
3
Combatting Antibiotic-Resistant : Discovery of TST1N-224, a Potent Inhibitor Targeting Response Regulator VraRC, through Pharmacophore-Based Screening and Molecular Characterizations.对抗抗生素耐药性：通过基于药效团的筛选和分子特征研究发现针对反应调节子 vraRC 的强效抑制剂 TST1N-224。
J Chem Inf Model. 2024 Aug 12;64(15):6132-6146. doi: 10.1021/acs.jcim.4c01046. Epub 2024 Jul 30.
4
Model-informed precision dosing in vancomycin treatment.万古霉素治疗中的模型引导精准给药
Front Pharmacol. 2023 Oct 9;14:1252757. doi: 10.3389/fphar.2023.1252757. eCollection 2023.
5
Divergent Total Synthesis and Characterization of Maxamycins.达佛霉素的发散全合成及结构表征。
J Am Chem Soc. 2023 Jun 14;145(23):12837-12852. doi: 10.1021/jacs.3c03710. Epub 2023 Jun 6.
6
Enterococcal Phages: Food and Health Applications.肠球菌噬菌体：食品与健康应用
Antibiotics (Basel). 2023 May 2;12(5):842. doi: 10.3390/antibiotics12050842.
7
Antibiotics and Carbohydrate-Containing Drugs Targeting Bacterial Cell Envelopes: An Overview.靶向细菌细胞壁的抗生素和含碳水化合物药物：概述
Pharmaceuticals (Basel). 2022 Jul 29;15(8):942. doi: 10.3390/ph15080942.
8
Regulation of Resistance in Vancomycin-Resistant Enterococci: The VanRS Two-Component System.耐万古霉素肠球菌耐药性的调控：VanRS双组分系统
Microorganisms. 2021 Sep 25;9(10):2026. doi: 10.3390/microorganisms9102026.
9
Does Vancomycin Wrapping in Anterior Cruciate Ligament Reconstruction Affect Tenocyte Activity In Vitro?前交叉韧带重建中万古霉素包裹是否会影响体外肌腱细胞活性？
Antibiotics (Basel). 2021 Sep 8;10(9):1087. doi: 10.3390/antibiotics10091087.
10
Enterococcus faecium: from microbiological insights to practical recommendations for infection control and diagnostics.屎肠球菌：从微生物学见解到感染控制和诊断的实用建议。
Antimicrob Resist Infect Control. 2020 Aug 10;9(1):130. doi: 10.1186/s13756-020-00770-1.
本文引用的文献
1
High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in The Netherlands: is the addition of antibiotics to animal feeds to blame?荷兰健康人群和猪中耐万古霉素和耐利奈唑胺肠球菌的高定植率：动物饲料中添加抗生素是罪魁祸首吗？
J Antimicrob Chemother. 1997 Sep;40(3):454-6. doi: 10.1093/jac/40.3.454.
2
Antimicrobial resistance--relation to human and animal exposure to antibiotics.抗生素耐药性——与人类和动物接触抗生素的关系。
J Antimicrob Chemother. 1997 Sep;40(3):453-4. doi: 10.1093/jac/40.3.453.
3
Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans.动物饲养中使用抗生素对人类细菌病原体耐药性的影响。
Ciba Found Symp. 1997;207:61-71; discussion 71-5. doi: 10.1002/9780470515358.ch5.
4
Resistance to glycopeptides in enterococci.肠球菌对糖肽类抗生素的耐药性。
Clin Infect Dis. 1997 Apr;24(4):545-54; quiz 555-6. doi: 10.1093/clind/24.4.545.
5
Antimicrobial resistance--use in veterinary and human medicine.
J Antimicrob Chemother. 1997 Mar;39(3):435. doi: 10.1093/jac/39.3.435.
6
Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States.来自美国医院、社区和动物源的耐万古霉素肠球菌。
Antimicrob Agents Chemother. 1996 Nov;40(11):2605-9. doi: 10.1128/AAC.40.11.2605.
7
Presence of vancomycin-resistant enterococci in farm and pet animals.农场动物和宠物中耐万古霉素肠球菌的存在。
Antimicrob Agents Chemother. 1996 Oct;40(10):2285-7. doi: 10.1128/AAC.40.10.2285.
8
Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster.丹麦动物源和人源屎肠球菌及粪肠球菌分离株的糖肽敏感性以及VanA基因簇内基因的PCR鉴定
Antimicrob Agents Chemother. 1996 Aug;40(8):1938-40. doi: 10.1128/AAC.40.8.1938.
9
Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans?在动物中使用包括糖肽类抗生素在内的抗菌剂，是否会影响人类抗菌治疗的疗效？
J Antimicrob Chemother. 1996 Feb;37(2):389-92. doi: 10.1093/jac/37.2.389.
10
Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci.
J Infect Dis. 1996 May;173(5):1292-4. doi: 10.1093/infdis/173.5.1292.
Zotero 插件